suspension separate the suspension into supernatant 1 and pellet,

holding the supernatant 1,

extracting the pellet a second time with H₂O at a temperature between 4-120°C, cooling the resulting suspension to between 40-60°C,

centrifuging the cooled suspension to separate the suspension into supernatant 2 and pellet,

pooling supernatant 1 with supernatant 2, and spray drying the pooled supernatants to obtain the shark cartilage extract.

REMARKS

In response to the Restriction Requirement, the applicants hereby elect Group I, claims 1, 2, 7, 8 and 15, drawn to a shark cartilage extract and pharmaceutical composition containing same. It is believed that new claims 16-18 can be examined with the elected Group, in view of 35 CFR 1.475 (b), which provides in subsection (3) that a product, a process specifically adapted for the manufacture of the product, and a use of the product can be maintained together. Claims 16 and 17 are directed to an anti-hypertensive use of the compound of claim 1, and claim 18 is directed to a method of making the claim 1 product. Accordingly, these claims should be maintained with the elected invention.

Furthermore, in view of the close relationship between claims 3 and 4, on the one hand, and claims 16 and 17 on the other hand, it is believed that claims 3 and 4 can be maintained with the elected invention without any extra burden on the Examiner, so that reconsideration, and combination of Groups I and II, is believed in order and is requested.

Likewise, the close relationship between claims 10-13 and new claim 18 indicates that claims 10-13 could be examined without any extra burden on the Examiner, so that it

is requested that the Restriction Requirement be further reconsidered and modified to include, with Groups I and II, Group VII.

The election is with traverse, as far as Groups I, II and VII are concerned, and without traverse with respect to the remaining Groups.

It is noted that in the International Preliminary Examining Report, the same Examiner found claims 3 and 4 to be novel, inventive and to have industrial applicability. Accordingly, it is believed that claims 3, 4, 16 and 17 are clearly in allowable condition. It is also believed that claim 1 and the remaining claims dependent thereon are also in allowable condition.

Modification of the Restriction Requirement, and early and favorable examination on the merits is requested and is awaited.

In the event any fees are required, please charge our Deposit Account No. 01-2300.

Respectfully submitted, Arent Fox Kintner Plotkin & Kahn, PLLC

Robert B. Murray

Registration No. 22,980

1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036-5339

(202) 857-6000

RBM/cb